{
    "name": "fluticasone intranasal",
    "comment": "Rx, OTC",
    "other_names": [
        "Flonase Allergy Relief",
        "ClariSpray",
        "Flonase Sensimist Allergy Relief",
        "Children's Flonase Allergy Relief",
        "Veramyst",
        "Xhance",
        "FlutiCare"
    ],
    "classes": [
        "Corticosteroids",
        "Intranasal"
    ],
    "source": "https://reference.medscape.com/drug/xhance-flonase-allergy-relief-clarispray-fluticasone-intranasal-999637",
    "pregnancy": {
        "common": [
            "Available data on inhaled or intranasal fluticasone propionate use in pregnant women have not reported a clear association with adverse developmental outcomes",
            "Fluticasone propionate crossed the placenta following subcutaneous administration to mice and rats and oral administration to rabbits"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There are no available data on fluticasone propionate in human milk, effects on breastfed child, or effects on milk production",
            "Developmental and health benefits of breastfeeding should be considered and adverse effects on breastfed child from treatment or from an underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to fluticasone or ingredients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May mask acute infection, including fungal infection, exacerbate viral infections or limit response to vaccines; not for use in untreated localized infection involving nasal mucosa; administer antimicrobial therapy if bacterial infection of sinuses suspected or confirmed; respiratory tract fungal or bacterial infections, parasitic infections, ocular herpes simplex may occur",
                "Persons who are using drugs that suppress the immune system, such as corticosteroids, are more susceptible to infections than healthy individuals and may experience a worsening of existing infections",
                "Chickenpox and measles: Serious or fatal course in susceptible individuals; unvaccinated or immunologically unexposed children or adults should avoid exposure",
                "Delays wound healing of nasal septal ulcers, trauma, or surgery; best to administer after healing has occurred",
                "May increase risk of hypercorticism or hypothalamic-pituitary adrenal (HPA) axis suppression, especially in younger patients receiving high doses for prolonged periods; HPA suppression may lead to adrenal crisis; withdraw or discontinue slowly; pediatric patients may be more susceptible to systemic toxicity",
                "Nasal corticosteroids, including fluticasone propionate, may result in the development of glaucoma and/or cataracts; closely monitor vision changes or patients with a history of increased intraocular pressure (IOP), glaucoma, and/or cataracts",
                "Systemic corticosteroids has shown to cause a reduction in growth velocity in children and adolescents; monitor growth while taking intranasal corticosteroids",
                "Decreases in bone mineral density (BMD) have been observed with long-term oral inhalation of products containing corticosteroids into lungs; monitor and appropriately treat patients with major risk factors for decreased bone mineral content (eg, prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass [eg, anticonvulsants, oral corticosteroids])",
                "Avoid in patients with known hypersensitivity to fluticasone or any ingredient; see Contraindications",
                "Avoid concomitant use with strong CYP3A4 (eg, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, conivaptan, lopinavir, voriconazole)"
            ],
            "specific": [
                {
                    "type": "Local nasal effects",
                    "description": [
                        "Epistaxis, nasal erosions, and nasal ulcerations were reported",
                        "Nasal septal perforations have been reported; patients treated over several months or longer should be examined periodically for possible changes in the nasal mucosa",
                        "If a septal perforation is noted, discontinue treatment; avoid spraying directly on septum",
                        "Localized Candida albicans infections have been observed; if such an infection develops, consider appropriate local therapy and discontinuation treatment; periodically examine for evidence of candidal infection in the nasal and oropharyngeal mucosa",
                        "Avoid use in patients who have experienced recent nasal ulcerations, nasal surgery, or nasal trauma"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nicardipine",
            "description": {
                "common": "nicardipine will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)",
            "description": {
                "common": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) will increase the level or effect of fluticasone intranasal by  unspecified interaction mechanism. Avoid or Use Alternate Drug. Coadministration may reduce serum cortisol concentrations; alternative corticosteroids should be considered, particularly for long term use."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir increases levels of fluticasone intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, fluticasone intranasal. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "tazemetostat will decrease the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nasal septal ulceration",
            "percent": "6.9"
        },
        {
            "name": "Nasal mucosal erythema",
            "percent": "5.6"
        },
        {
            "name": "Headache",
            "percent": "5"
        },
        {
            "name": "Nasal congestion",
            "percent": "4.4"
        },
        {
            "name": "Acute sinusitis",
            "percent": "4.4"
        },
        {
            "name": "Nasal mucosal ulceration",
            "percent": "3.8"
        },
        {
            "name": "Nasal septal erythema",
            "percent": "3.8"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "1.9"
        },
        {
            "name": "Pharyngitis",
            "percent": "1.3"
        },
        {
            "name": "Epistaxis",
            "percent": "9.9"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "7.5"
        },
        {
            "name": "Nasal septal ulceration",
            "percent": "7.5"
        },
        {
            "name": "Nasal congestion",
            "percent": "5.6"
        },
        {
            "name": "Acute sinusitis",
            "percent": "5"
        },
        {
            "name": "Nasal mucosal erythema",
            "percent": "5"
        },
        {
            "name": "Nasal septal erythema",
            "percent": "4.3"
        },
        {
            "name": "Headache",
            "percent": "3.7"
        },
        {
            "name": "Pharyngitis",
            "percent": "3.1"
        },
        {
            "name": "Nasal mucosal ulceration",
            "percent": "2.5"
        },
        {
            "name": "Nasal dryness",
            "percent": "1"
        },
        {
            "name": "Sinusitis",
            "percent": "1"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "1"
        },
        {
            "name": "Toothache",
            "percent": "1"
        },
        {
            "name": "Intraocular pressure increase",
            "percent": "1"
        }
    ]
}